Received by email:

File: 4.2.19 Imagin Functional Unit FINAL.docx



IMAGIN MEDICAL COMPLETES ASSEMBLY OF 
i/BLUE(TM) IMAGING SYSTEM FUNCTIONAL UNIT
_________________________________________________

Vancouver, B.C. and Boston, MA, April 2, 2019 - Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol
--->: DPD2) ("Imagin" or the "Company") today announced that it reached the first step of a major product development mile
--->stone with completion of the i/Blue Imaging System's Functional Unit, which has successfully met the Company's pre-est
--->ablished performance expectations.

Following the typical product development path for a new medical technology, the Company is working to move the i/Blue
---> Imaging System through various progressive stages: original design, proof of principle prototype, functional system, 
--->pilot production, product validation and, finally, realized product for commercialization. 

Today's announcement confirms completion of the first step of the functional system stage, with both components of the
---> Functional Unit - the System Control Unit and Dual Camera Handpiece - operating as anticipated to provide simultaneou
--->s high-resolution images in both blue and white light modes. The System Control Unit, which houses the previously veri
--->fied light source, camera controller and power supply modules, is designed to work in conjunction with the Dual Camera
---> Handpiece. Data from the previous Research Study conducted at the University of Rochester Medical Center was used to 
--->refine and optimize the technology for performance, size and cost, resulting in a current Functional Unit that is 70% 
--->smaller than the proof of principle prototype. 

The final steps in the functional system phase include building additional units with enhanced software that will be v
--->erified for multiple functions - such as electrical safety, and reprocessing and sterilization - and completing simula
--->ted packaging and shipping activities. Imagin anticipates these critical milestones will be completed by mid-year, pos
--->itioning the Company to initiate the pilot production and product validation stages. 

"We are very pleased that the i/Blue Imaging System's Functional Unit is performing as intended," said Jim Hutchens, I
--->magin's President and CEO. "We are currently conducting focus groups with urologists to optimize the software user int
--->erface and to meet precise functionality requirements."

Mr. Hutchens continued, "We believe that the i/Blue technology's many advantages, combined with product's expected pri
--->ce point, have significant potential for bringing blue light cystoscopy into the mainstream standard of care for bladd
--->er cancer. We are excited to see the real promise of Imagin's ground-breaking technology start to emerge and believe t
--->hat it will drive significant value for our shareholders as we progress."

About Imagin Medical

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer duri
--->ng minimally invasive surgeries. The Company believes its first product, the i/BlueTM Imaging System, will dramaticall
--->y improve surgeons' ability to visualize cancerous cells by producing higher-quality images more quickly compared with
---> current methods. Based on advanced optics and light sensors, the i/Blue Imaging System employs patented ultrasensitiv
--->e imaging technology and offers easy-to-use viewing options for more accurate resection. The Company's initial focus i
--->s bladder cancer. Learn more at www.imaginmedical.com.

Forward-Looking Statements 

Information set forth in this news release contains forward-looking statements. These statements reflect management's 
--->current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company ca
--->utions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a 
--->number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, con
--->ditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implie
--->d in the forward-looking information. Specifically, there is no assurance the Company's imaging system will work in th
--->e manner expected.  Except as required under applicable securities legislation, the Company undertakes no obligation t
--->o publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information 
--->contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contacts:

Stephen Kilmer, Investor Relations 
Telephone: 647-872-4849
Email: stephen@kilmerlucas.com 

Jim Hutchens, President & CEO
Telephone: 833-246-2446

NR-2019-IME #31